Review Article

Tubercular Meningitis in Children: An Update

KANIJ FATEMA,1 MD MIZANUR RAHMAN,2 SHAHEEN AKTER 3, SURAIYA BEGUM4

Introduction:
Central nervous system (CNS) tuberculosis (TB) accounts for approximately 1% of all of disease caused by Mycobacterium tuberculosis but kills and disables more sufferers than any other form of tuberculosis. Tubercular meningitis (TBM) is the most common form of CNS tuberculosis which causes substantial morbidity and mortality in adults and children. The worldwide prevalence of TB in children is difficult to assess because data are scarce and poorly organized. The available reports grossly underestimate the true incidence. The developing world has 1.3 million cases of TB and 40,000 TB-related deaths annually among children younger than 15 years. In these countries, 10-20% of people who die of TB are children. TBM complicates approximately 1 of every 300 untreated primary TB infections.1 Early diagnosis and treatment is very important as if treated early, most patients recover completely, but if the disease progress untreated, death and disability are very common despite microbiological cure.2 The diagnosis and management of TBM challenges physicians throughout the world. This article is targeted to discuss about the update of clinical characteristics, investigations and treatment of TBM.

Clinical Manifestations
TBM is a disease of young children with 40% patients under 2 years of age and 70% under 5 years at the time of presentation.1 The clinical presentation of TBM is non-specific, especially in the early stages of disease. Most patients present with a vague ill health lasting 2-8 weeks prior to the development of meningeal irritation. These nonspecific symptoms include malaise, anorexia, fatigue, fever, myalgias and headache. Children with TBM often present with neck stiffness, seizure and abdominal symptoms such as nausea and vomiting. The neurological picture is mostly the result of combined effect of increased intracranial pressure and infarction.2 A history of contact is identified in approximately 50 to 60‰ of children. A close association with disseminated tuberculosis is seen in pediatric age. Cranial nerve palsies occur in 20-30‰ of patients. The sixth cranial nerve is most commonly affected. Vision loss due to optic nerve involvement may occasionally be a dominant presenting illness. Ophthalmoscopic examination may reveal papilloedema and choroid tubercle.3, 4

Table-I
Consensus tuberculous meningitis diagnosis 5

Clinical entry criteria
• Symptoms and signs of meningitis including one or more of the following: headache, irritability, vomiting, fever, neck stiffness, convulsions, focal neurological deficits, altered consciousness, or lethargy.

Tuberculous meningitis classification

Definite tuberculous meningitis
• Patients should fulfill criterion A or B:
  A) Clinical entry criteria plus one or more of the following: acid-fast bacilli seen in the CSF; Mycobacterium tuberculosis cultured from the CSF; or a CSF positive commercial nucleic acid amplification test.
  B) Acid-fast bacilli seen in the context of histological changes consistent with tuberculosis in the brain or spinal cord with suggestive symptoms or signs and CSF changes, or visible meningitis (on autopsy).

Probable tuberculosis meningitis
• Clinical entry criteria plus a total diagnostic score of 10 or more points (when cerebral imaging is not available) or 12 or more points (when cerebral imaging is available) plus exclusion of alternative diagnoses. At least 2 points should either come from CSF or cerebral imaging criteria.

Possible tuberculosis meningitis
• Clinical entry criteria plus a total diagnostic score of 6–9 points (when cerebral imaging is not available) or 6–11 points (when cerebral imaging is available) plus exclusion of alternative diagnoses. Possible tuberculosis cannot be diagnosed or excluded without doing a lumbar puncture or cerebral imaging.

Not tuberculosis meningitis
• Alternative diagnosis established, without a definitive diagnosis of tuberculous meningitis or other convincing signs of dual disease.

1. Assistant Professor, Pediatric Neurology, BSMMU.
2. Professor and Head, Pediatric Neurology, BSMMU
3. Professor, Pediatric Neurology, BSMMU.
4. Associate Professor, General Pediatrics, BSMMU.

Correspondence: Dr Kanij Fatema, Assistant Professor, Pediatric Neurology, BSMMU.
### Table-II

*Diagnostic criteria for classification of definite, probable, possible, and not tuberculous meningitis*

#### Clinical criteria (Maximum category score=6)
- Symptom duration of more than 5 days: 4
- Systemic symptoms suggestive of tuberculosis (one or more of the following): weight loss (or poor weight gain in children), night sweats, or persistent cough for more than 2 weeks: 2
- History of recent (within past year) close contact with an individual with pulmonary tuberculosis or a positive TST or IGRA (only in children <10 years of age): 2
- Focal neurological deficit (excluding cranial nerve palsies): 1
- Cranial nerve palsy: 1
- Altered consciousness: 1

#### CSF criteria (Maximum category score=4)
- Clear appearance: 1
- Cells: 10–500 per µl: 1
- Lymphocytic predominance (>50%): 1
- Protein concentration greater than 1 g/L: 1
- CSF to plasma glucose ratio of less than 50% or an absolute CSF glucose concentration less than 2.2 mmol/L: 1

#### Cerebral imaging criteria (Maximum category score=6)
- Hydrocephalus: 1
- Basal meningeal enhancement: 2
- Tuberculoma: 2
- Infarct: 1
- Pre-contrast basal hyperdensity: 2

#### Evidence of tuberculosis elsewhere (Maximum category score=4)
- Chest radiograph suggestive of active tuberculosis: signs of tuberculosis=2; miliary tuberculosis=4
- CT/ MRI/ ultrasound evidence for tuberculosis outside the CNS: 2
  - AFB identified or *Mycobacterium tuberculosis* cultured from another source—ie, sputum, lymph node, gastric washing, urine, blood culture: 4
  - Positive commercial *M tuberculosis* NAAT from extra-neural specimen: 4

TST=tuberculin skin test. IGRA=interferon-gamma release assay. NAAT=nucleic acid amplification test. AFB=acid-fast bacilli.

### Table-III

*Comparison of the presenting clinical variables independently predictive of tuberculous meningitis in five published studies*

<table>
<thead>
<tr>
<th>Study</th>
<th>Setting</th>
<th>Age group</th>
<th>Variables predictive of tuberculous meningitis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kumar et al, 1999</td>
<td>Children (1month-12 year)</td>
<td>History of illness &gt;6 days, CSF lymphocytes &gt;50% of total white cells, Optic atrophy, Abnormal movement, Focal neurological deficit</td>
</tr>
<tr>
<td></td>
<td>Youssef et al, 2006</td>
<td>Children and adult (5 months to 56 year)</td>
<td>History of illness &gt;5 days, CSF lymphocytes &gt;30% of total white cells, CSF white cell &lt;1000, Clear CSF, CSF protein &gt;100 mg/dl</td>
</tr>
<tr>
<td></td>
<td>Thwaites et al, 2002</td>
<td>Adults (16-70 years)</td>
<td>History of illness &gt;6 days, CSF lymphocytes &gt;10% of total white cells, CSF white cell &lt;750, Age &lt;36 years, Total WBC of blood &lt;15000/cu mm</td>
</tr>
<tr>
<td></td>
<td>Moghtaderi et al, 2009</td>
<td>Older children and adults (9-80 years)</td>
<td>History of illness &gt;5 days, CSF lymphocytes &gt;70% of total white cells, CSF white cell &lt;1000/HPF, Age &gt;30 years</td>
</tr>
</tbody>
</table>
Staging: Outcome of TBM relates closely to the stage of disease at the time treatment is begun. Apart from having prognostic value in the individual patient, staging is also important when treatment modalities in different studies are compared. The British Medical Research Council introduced a three-stage classification system in 1948. During the 1970s this staging was modified to include the Glasgow Coma Scale (GCS) and more recently ‘refined’ to improve prognostic accuracy. The refined MRC scale is as follows.

Stage 1: GCS score of 15/15 with no focal neurological sign.

Stage 2a: GCS score of 15 with no neurological deficit or a GCS score of 13-14 with or without neurological deficit.

Stage 2b: GCS score of 10-12 with or without neurological deficit.

Stage 3: GCS score <10.

Investigation:

The diagnosis of TBM can be difficult. Most important is CSF study. In this section we will discuss how the conventional and advanced investigations help in the diagnosis of TBM.

CSF study: Characteristic CSF findings of TBM include the following: (i) lymphocytic-predominant pleiocytosis. Total white cell counts are usually between 100 and 500 cells/ìL. Very early in the disease, lower counts and neutrophil predominance may be present. (ii) elevated protein levels, typically between 100 and 500 mg/dL. (iii) low glucose, usually less than 45mg/dL or CSF: plasma ratio <0.5. Atypical CSF findings have been described, including normal CSF glucose, protein, cell count, or a neutrophil predominance. Rare cases of culture-proven TBM with no other CSF abnormalities have also been reported.

AFB staining: Definitive diagnosis of TBM depends upon the detection of the tubercle bacilli in the CSF, either by smear examination or by bacterial culture. Standard staining techniques are Ziehl-Neelsen, Kinyoum, or auramine-rhodamine. These can detect approximately 100 AFB/ml of CSF. The ZN stain is a faster method of diagnosis but a single sample has low sensitivity, on the order of 20%-40%. Several daily large volume (10–15 mL) lumbar punctures are often needed for microbiologic diagnosis; sensitivity increases to >85% when four spinal taps are performed.

Culture: The gold standard for the diagnosis of TBM is the growth of M. tuberculosis from the CSF, but 4 to 8 weeks are required for cultures to become positive and up to 45% of patients with presumed TBM have negative CSF cultures. There is a variety of culture media used which include egg-based (Lovenstein-Jensen-LJ, Petragnani, American Trudeau Society, and Ogawa), agar-based (Middlebrook 7H10 and 7H11) and liquid media (Middlebrook 7H9, Kirchner, BioFM and Dubos). Due to the slow growth of the organism (40 to 60 days), this exam is useful only from an epidemiological point of view. The BACTEC radiometric method has been used for several years for rapid isolation of bacteria. Recently, the BACTEC method has been used for the isolation of M. tuberculosis in CSF specimens. Studies have demonstrated several advantages of using the method, including higher yield and more rapid isolation of M. tuberculosis. The time required for isolating bacteria is average 15 days.

ADA: CSF Adenosine Deaminase activity (ADA) is a marker of cell-mediated immunity. It was found that ADA values less than 4 U/L excludes TBM and greater than 8 U/L are suggestive of TBM. CSF ADA e•10 U/L has >90% sensitivity and specificity of diagnosing TBM. However, false-positive ADA can be found in patients infected with HIV, cryptococcal meningitis, lymphomatous meningitis, and cytomegalovirus disease. Thus it is not recommended as a routine diagnostic test for TBM.

NAA: Commercial nucleic acid amplification (NAA) assay can confirm TBM (specificity 98%) but cannot rule it out (sensitivity 56%). The sensitivity of CSF microscopy and culture falls rapidly after the start of treatment, whereas mycobacterial DNA may remain detectable within the CSF until one month after the start of treatment. So because of its high specificity, a positive NAA test is regarded as a definitive test in patients with suspected TBM, and offers particular value in patients who have previously received treatment.

Xpert MTB/RIF assay: The Xpert MTB/RIF is a new fully automated diagnostic molecular test that simultaneously detects the presence of multidrug resistant tuberculosis (MTB) and rifampicin resistance in specimens, using nested real-time(sensitivity 67-85%, specificity 94-98%). The advantages are the ease of use for inexperienced staff and rapid turnover.
time (about 2 h). Its ability to detect rifampicin resistance within 2 h may lead to an important improvement in the management of Multidrug resistant TB (MDR-TB). The World Health Organization (WHO) has recently endorsed the implementation of the Xpert MTB/RIF assay for national tuberculosis programmes in developing countries.\(^\text{13}\)

**MT:** The result of the tuberculin skin test for the diagnosis of tuberculosis varies according to age, vaccination with BCG, nutritional status, HIV infection, and technique of administration.\(^\text{14}\) Additionally, a positive tuberculin skin test does not differentiate M tuberculosis infection (which is a common event in tuberculosis endemic areas) from active disease. The diagnostic utility of skin testing being positive for CNS tuberculosis varies from 10-50%\(^\text{2,15}\).

Other immunological tests available are interferon gamma release assay (IGRA), ELISA etc. Pretreatment peripheral blood INF-\(\gamma\) enzyme-linked immunospot (ELISPOT) response has not shown any advantage over conventional bacteriological diagnosis in adults but has not been evaluated in children\(^\text{2}\) A systematic review of commercially available antibody detection concluded that such tests have no role in the diagnosis of extrapulmonary tuberculosis.\(^\text{16}\)

A complete blood count should be performed, and the erythrocyte sedimentation rate should be determined. Blood count show leukopenia and/or normal WBC count, but leukocytosis and neutrophilia have been reported in some patients with TBM. There may elevated ESR . The serum glucose level should be measured; this value is a useful comparison with the glucose level measured in the CSF. In addition to this, serum electrolyte, liver function test and renal function test should be done which may show hypometraemia due to development of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in about 45%.\(^\text{17}\)

**Neuroimaging:** Neuroimaging is very important in diagnosis of TBM. Cranial computerized tomography(CT) and more recently MRI are extremely helpful in diagnosing and managing TBM and its complications.\(^\text{18}\) Classic CT triad of TBM consists of basal meningovascular enhancement, obstructive hydrocephalus and cerebral infarction, most commonly of the basal ganglia. One study found that combination of hydrocephalus, basal enhancement and infarction is 100% specific and 41% sensitive for the diagnosis of childhood TBM. although the authors suggested pre-contrast hyperdensity in the basal cisterns as the best predictor of TBM.\(^\text{19,20}\)

Magnetic resonance imaging (MRI) is the imaging test of choice for visualizing abnormalities associated with TBM. It shows diffuse, thick, meningeal enhancement. Contrast enhanced MRI is generally considered as the modality of choice. It is useful for assessment of the location of lesions and their margins, as well as ventriculitis, meningitis and spinal involvement (sensitivity 86%, specificity 90%). The T2-weighted MRI imaging has been shown to be particularly good at demonstrating brainstem pathology; diffusion-weighted imaging (DWI) is best at detection of acute cerebral infarcts due to TBM. Tuberculoma is best evaluated in MRI. The appearance of a solid caseous tuberculoma is that of an isointense or mildly hyperintense brain lesion with marked surrounding low density that demonstrates vasogenic oedema. Marked rim enhancement is always present after contrast administration. A hypointense centre indicates liquefaction and abscess formation.\(^\text{2}\) Tuberculous abscesses are larger than tuberculomas (often >3 cm in diameter), solitary, thin walled, and often multi-loculated.\(^\text{21}\) DWI in tuberculous abscesses has shown restricted diffusion with low apparent diffusion coefficient (ADC) values, probably a result of the presence of intact inflammatory cells in the pus. Unfortunately these radiological features are not specific for tuberculoma. The differential diagnosis of solid tuberculoma includes toxoplasmosis and cerebral tumours, while cystic tuberculomas cannot be differentiated from pyogenic brain abscess and neurocysticercosis on usual imaging alone.\(^\text{2,22}\)

A large lipid, lactate peak has been used to identify tuberculomas by magnetic resonance spectroscopy (MRS). Serial transcranial doppler ultrasonography (TCD) with blood flow velocity and pulsatility index measurements, can be efficiently utilized to prognosticate outcome in tuberculous meningitis related vasculopathy.\(^\text{23}\)

Air encephalography is the most reliable way of determining the level of CSF obstruction. If in lateral skull x-ray, air in the basal cistern and lateral ventricles indicates communicating hydrocephalus but air only at the level of basal cistern indicates noncommunicating hydrocephalus.\(^\text{2}\)

**Treatment**

**Antimicrobial therapy:** TBM is a medical emergency and treatment should be initiated as soon as the condition is suspected because delay is associated with death and disability. Therefore empiric treatment
should be started as soon as TBM is suspected clinically.\textsuperscript{2} The recommended treatment regimen for presumed drug susceptible TBM consists of two months of daily Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), and either Streptomycin (SM), or Ethambutol (EMB), followed by 10 months of INH and RIF.\textsuperscript{24}

INH is considered the most critical of the first-line agents due to its excellent CSF penetration and high bactericidal activity. CSF penetration of INH is about 90 to 95\%.\textsuperscript{7} While RIF penetrates the CSF less freely (5\%–25\%). However, the high mortality of TBM due to RIF-resistant strains has confirmed its importance. PZA has excellent penetration into the CSF (95\%–100\%) and is a key drug in reducing the total treatment time for drug-susceptible TBM. Hence, if PZA cannot be tolerated, the treatment course for TBM should be lengthened to a total of 18 months.\textsuperscript{4}

INH kills most of the rapidly replicating bacilli in the first 2 weeks of treatment, with some additional help from SM and EMB. Thereafter, RIF and PZA become important because they “sterilize” lesions by killing organisms; RIF kills low or non-replicating organisms and PZA kills those in sites hostile to the penetration and action of the other drugs.\textsuperscript{4}

The 4th drug: There are no data from controlled trials to guide choice of the fourth drug. Most authorities recommend either Streptomycin or ethambutol, although neither penetrates the CSF well in the absence of inflammation, and both can produce significant adverse reactions. SM should not be given to those who are pregnant or have renal impairment and resistance is relatively common worldwide. While EMB-induced optic neuropathy is a concern, especially when treating comatose patients, although at the standard dose of 15 - 20 mg/kg, the incidence is less than 3\%.\textsuperscript{25}

Some researchers advocate ethionamide, particularly in South Africa. Ethionamide penetrates healthy and inflamed meninges, but can cause severe nausea and vomiting.\textsuperscript{25}

Duration: Evidence concerning the duration of treatment is conflicting. The duration of conventional therapy is 6-9 months, although some investigators still recommend as many as 24 months of therapy. In the national guideline of Bangladesh for treatment of tuberculosis in children, the recommended duration is 12 month.\textsuperscript{26} WHO recommendation for duration is 12 months.\textsuperscript{27} Recently, in a study it has been shown that short course intensified treatment (6 months INH, RIF, PZA, Ethambutol for HIV uninfected and 9 months for HIV infected patients) is safe for drug susceptible cases.\textsuperscript{28,29}

### Table-V

**First-line treatment regimens for tuberculous meningitis in children WHO and UK recommendations\textsuperscript{26}**

<table>
<thead>
<tr>
<th>Antituberculosis drugs</th>
<th>Daily dose in children</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (INH)</td>
<td>10–20 mg/kg (maximum 500 mg)</td>
<td>12 months</td>
</tr>
<tr>
<td>Rifampicin (RIF)</td>
<td>10–20 mg/kg (maximum 600 mg)</td>
<td>12 months</td>
</tr>
<tr>
<td>Pyrazinamide (PZA)</td>
<td>15–30 mg/kg (maximum 2 g)</td>
<td>2 months</td>
</tr>
<tr>
<td>Ethambutol (EMB)</td>
<td>15–20 mg/kg (maximum 1 g)</td>
<td>2 months</td>
</tr>
</tbody>
</table>

### Table-V

**National Guideline (Bangladesh) for treatment of TBM\textsuperscript{26}**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Daily dose and range (mg per kg body weight)</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoniazid (H)</td>
<td>10 (5-15) [maximum 300mg]</td>
<td>12 months</td>
</tr>
<tr>
<td>Rifampicin (R)</td>
<td>15 (10-20) [maximum 600mg]</td>
<td>12 months</td>
</tr>
<tr>
<td>Pyrazinamide (Z)</td>
<td>35 (30-40) [maximum 2000mg]</td>
<td>2 months</td>
</tr>
<tr>
<td>Streptomycin (S)</td>
<td>15 (12-18) [maximum 1000mg]</td>
<td>2 months</td>
</tr>
</tbody>
</table>

**Corticosteroids:** Adjunctive corticosteroid increases the survival of patients, improve symptom and seizure control and reduce tuberculoma size and peri-lesional
oedema. One possible explanation for the survival benefit is that the anti-inflammatory effects of corticosteroids reduce the number of severe adverse events (9.5% versus 16%), particularly hepatitis. Since there are no controlled trials comparing corticosteroid regimens, treatment choice should be based on those found to be effective in published trials. One recommended regimen for severe TBM is intravenous dexamethasone for four weeks (1 week each of 0.4mg/kg/day, 0.3 mg/kg/day, 0.2mg/kg/day, and 0.1mg/kg/day followed by four weeks of tapering oral dexamethasone therapy. WHO recommendation is dexamethasone 0.6mg/kg/day intravenous initially and then orally. It is recommended to reduce the dose weekly to stop over 6-8 weeks. Oral prednisolone can also be given as adjunctive therapy at the dose of 2mg/kg/day for six weeks.

MDR TBM: TBM resistant to INH and RIF is described as MDR. No controlled trials have been published for the treatment of MDR TBM. Clinicians of patients with MDR-TBM are left to extrapolate from guidelines for the treatment of pulmonary MDR-TB. The World Health Organization recommends for pulmonary MDR-TB the use of a minimum of four agents to which the M. tuberculosis strain has known or suspected susceptibility including use of any first-line oral agents to which the strain remains susceptible, an injectable agent (i.e., an aminoglycoside or capreomycin), a FQN, and then adding other second-line agents as needed for a total of at least four drugs.

Role of other drugs: Ischemic brain damage is the most important reason for the permanent neurological sequelae in TBM. Aspirin is used in this cases due to antithrombotic, anti-ischemic and anti-inflammatory properties. However, in adult Aspirin showed significant reduction in mortality at 3 month while in children it showed no significant improvement in mortality and morbidity at 6 months. Another drug is Thalidomide which is an immunomodulatory agent. In two case series of tuberculomas and
tubercular abscess and blindness due to optic arachnoiditis showed dramatic clinical and neuroradiological improvement after low dose of thalidomide. However, caution should be taken as it produces serious side effects. 32 Fluoroquinolones could represent highly effective fourth drugs and are an essential component of treatment regimens for multidrug-resistant cases. Vitamin D supplementation may play role in TBM as in few studies it has been seen that there is an association between tuberculous meningitis and low sunshine hours 3 months before disease. It suggests a possible role for low vitamin D in bacterial dissemination. 28

**Fluid Management in TBM:** Hyponatraemia is common in TBM and has been related to stage of disease, cerebral perfusion pressure and clinical outcome. It may result from syndrome of inappropriate ADH (SIADH) or cerebral salt wasting (CSWS). Patients with SIADH are euvoalaemic or hypervoalaemic and need fluid restriction while CSWS is associated with hypovolaemia and requires fluid replacement. A positive fluid balance in TBM is important as there is risk of stroke. In addition diuretic treatment of hydrocephalus should be initiated only once the patient’s hydration status has normalized. 2

**Conclusion:** TBM is a devastating disease. Despite undeniable advances in the investigation in recent years, most of the problems that pediatricians and neurologists face have been solved by the uniform definition of TBM. Still some challenges are yet to solve. Most important are consensus regarding the 4th drug and MDR TBM treatment. Therefore, new studies in children are urgently suggested. In the meantime, when treating a child with suspected TBM, the most aggressive attitude is to be used both for diagnosis and for therapy.

**References:**


14. Van der Weert EM, Hartgers NM, Schaaf HS. Comparison of diagnostic criteria of tuberculous


29. Van Toorn R, Schaaf HS, Laubscher JA. Short intensified treatment in children with drug susceptible tubercular meningitis. Pediatric Infectious Disease Journal 2013; (Epub )

